Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
$3.95
+8.8%
$3.90
$3.19
$6.82
$169.38M1.17128,659 shs106,667 shs
Immuneering Corporation stock logo
IMRX
Immuneering
$4.06
-8.2%
$2.29
$1.00
$4.60
$146.00M0.381.39 million shs913,441 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$5.75
-1.8%
$4.28
$2.92
$11.20
$37.06M-1.8873,049 shs80,844 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.59
+4.8%
$12.65
$6.12
$27.38
$158.52M0.43156,980 shs135,262 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
0.00%-0.55%-0.55%+2.54%+4.61%
Immuneering Corporation stock logo
IMRX
Immuneering
0.00%+30.38%+132.63%+240.00%+256.45%
KALA BIO, Inc. stock logo
KALA
KALA BIO
0.00%+10.59%+36.05%+67.62%-21.79%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-4.11%-3.38%-15.72%+96.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
1.1986 of 5 stars
3.50.00.00.02.70.00.0
Immuneering Corporation stock logo
IMRX
Immuneering
3.4225 of 5 stars
3.32.00.00.03.35.00.6
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.9569 of 5 stars
3.52.00.04.42.30.80.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.3372 of 5 stars
3.50.01.72.73.82.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
3.00
Buy$8.00112.20% Upside
Immuneering Corporation stock logo
IMRX
Immuneering
2.60
Moderate Buy$13.25216.46% Upside
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.00
Buy$13.00122.79% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50151.24% Upside

Current Analyst Ratings Breakdown

Latest KALA, DMAC, IMRX, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/5/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/2/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$15.00
5/29/2025
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/23/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/7/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.00
5/6/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/A$0.95 per shareN/A
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/A$1.33 per shareN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.89M9.68N/AN/A$2.02 per share2.89
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.76$0.89 per share13.62$2.05 per share5.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
-$24.44M-$0.64N/AN/AN/AN/A-61.35%-55.53%8/6/2025 (Estimated)
Immuneering Corporation stock logo
IMRX
Immuneering
-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%8/5/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6917.58N/A4.12%34.67%15.24%8/27/2025 (Estimated)

Latest KALA, DMAC, IMRX, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
-$0.18N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.40N/AN/AN/AN/AN/A
8/5/2025Q2 2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$1.82N/AN/AN/AN/AN/A
5/13/2025Q1 2025
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
-$0.18-$0.18N/A-$0.18N/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/5/2025Q1 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.41-$0.42-$0.01-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.48%N/A26.09%3 Years

Latest KALA, DMAC, IMRX, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
N/A
8.02
8.02
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
7.48
7.48
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.19
1.99
1.99
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98

Institutional Ownership

CompanyInstitutional Ownership
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
10.12%
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
7.30%
Immuneering Corporation stock logo
IMRX
Immuneering
22.90%
KALA BIO, Inc. stock logo
KALA
KALA BIO
8.32%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
2042.88 million39.75 millionOptionable
Immuneering Corporation stock logo
IMRX
Immuneering
6035.99 million27.75 millionNot Optionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
306.45 million5.92 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable

Recent News About These Companies

LifeVantage Declares Quarterly Dividend
LifeVantage: Activation Of Shareholder Value
LifeVantage (LFVN) Receives a Buy from Lake Street

New MarketBeat Followers Over Time

Media Sentiment Over Time

DiaMedica Therapeutics stock logo

DiaMedica Therapeutics NASDAQ:DMAC

$3.96 +0.33 (+9.04%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Immuneering stock logo

Immuneering NASDAQ:IMRX

$4.08 -0.34 (-7.69%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$5.79 -0.06 (-0.96%)
As of 02:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.52 +0.51 (+4.25%)
As of 02:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.